June 6, 2022

Brian P. Waldman
ArentFox Schiff LLP
1717 K Street, N.W.
Washington, DC 20006

Sent via email to: Brian.Waldman@afslaw.com

Dear Petitioner:

Your submission requesting the Commissioner of Food and Drug declare that Ascorbic Acid Injection, USP, 2,500 mg/5 mL (500 mg/mL) and 5,000 mg/10 mL (500 mg/mL) are suitable for submission in an ANDA was received and processed under CFR 10.30 by this office on 06/03/2022.

It was assigned docket number FDA-2022-P-0979. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note, the acceptance of the suitability petition for filing is a procedural matter and in no way reflects the Agency's decision on the substantive merits of the petition.

Sincerely,

Karen P. Malvin -S
Digitally signed by Karen P. Malvin -S
Date: 2022.06.06 09:37:58 -04'00'

Karen Malvin
Acting Director
Dockets Management Staff
FDA/Office of Operations (OO)